Mirum Pharmaceuticals, Inc. (MIRM) Stock
MIRM has an Alpha Score of 30 out of 100 (poor), computed on Aug 29, 2026 from 3 of 4 sub-scores. 3 of the hedge funds AlphaScala tracks reported MIRM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $51.77M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
What is MIRM's Alpha Score?
How it works →Alpha Score of 30 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 29, 2026 · 54 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own MIRM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 442K | $51.77M | -24% |
| Millennium Management Israel Englander | 96K | $11.26M | -74% |
| D.E. Shaw David Shaw | 28K | $3.26M | -83% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Mirum Pharmaceuticals, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 14, 26 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | SELL | 9.9K | $978K |
| Sep 2, 26 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 658 | $66K |
| Sep 1, 26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 8.3K | $815K |
| Sep 1, 26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 21.7K | $2.1M |
| Aug 18, 26 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 40.0K | $4.0M |
| Aug 11, 26 | Bjerkholt Eric | CHIEF FINANCIAL OFFICER | SELL | 6.0K | $600K |
| Aug 10, 26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 11.7K | $1.2M |
| Aug 10, 26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 6.0K | $597K |
| Aug 10, 26 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 2.3K | $230K |
| Aug 3, 26 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 1.8K | $194K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are MIRM's key statistics?
Key statistics as of Oct 21, 2026
How does MIRM's valuation compare with the Healthcare sector?
| Metric | MIRM | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -139.18% | 9.40% | 92 |
| Return on equity | -289.33% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
MIRM price chart
Powered by TradingViewWhat does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases. Its primary objective is to address unmet medical needs, particularly in the sphere of liver diseases where few treatment options exist. Mirum is especially recognized for its work on conditions like Alagille syndrome, a rare genetic disorder affecting the liver, heart, and other parts of the body. The company is committed to advancing its research to offer novel solutions, facilitating regulatory approval processes, and ensuring global access to its therapies. Mirum Pharmaceuticals plays an essential role in the healthcare sector, providing essential treatment options that can significantly improve the quality of life for patients with chronic and challenging illnesses. Its contributions are vital for advancements in the understanding and management of complex liver diseases, making it a key player in the biopharmaceutical landscape, serving the needs of niche patient populations with precision medicine.